drugset / Trial / NCT06409130
Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The study will look at the effects of NNC0194-0499, cagrilintide and semaglutide, on liver damage and alcohol use in participants with alcoholic liver disease. Participants will get NNC0194-0499, semaglutide, cagrilintide or ''dummy" medicine in different treatment combinations. Which treatment participants get is decided by chance. The study will last for about 39 weeks.
Timeline
- Start
- 2024-05-20
- Primary completion
- 2025-11-21
- Completion
- 2026-01-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cagrilintide | Protein / enzyme biologic | — | Subcutaneous |
| Subject | Semaglutide | Peptide | — | Subcutaneous |
| Subject | zalfermin | Protein / enzyme biologic | — | Subcutaneous |